Evidence map›Paper›PMID 39349464›Full record

ArticleNature communications2024

A structural rationale for reversible vs irreversible amyloid fibril formation from a single protein.

Lukas Frey, Jiangtao Zhou, Gea Cereghetti, Marco E Weber, David Rhyner, Aditya Pokharna, Luca Wenchel, Harindranath Kadavath, Yiping Cao, Beat H Meier and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. From Disordered to Ordered: Nanoscale Spectroscopy Reveals Structural Evolution of Amyloid Beta 40 Fibrils.Chemphyschem : a European journal of chemical physics and physical chemistry · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lukas Frey *Institute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland.ORCID 0000-0002-1052-1104
Jiangtao Zhou *ETH Zurich, Department of Health Sciences and Technology, Zurich, Switzerland. jiangtao.zhou@hest.ethz.ch.ORCID 0000-0003-4248-2207
Gea CereghettiInstitute of Biochemistry, Department of Biology, ETH Zurich, Zurich, Switzerland.ORCID 0000-0001-7732-9435
Marco E WeberInstitute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland.ORCID 0000-0001-9764-4862
David RhynerInstitute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland.
Aditya PokharnaInstitute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland.
Luca WenchelInstitute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland.
Harindranath KadavathInstitute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland.ORCID 0000-0002-4559-4389
Yiping CaoDepartment of Food Science and Technology, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
Beat H MeierInstitute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland.
Matthias PeterInstitute of Biochemistry, Department of Biology, ETH Zurich, Zurich, Switzerland.ORCID 0000-0002-2160-6824
Jason GreenwaldInstitute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland.
Roland RiekInstitute of Molecular Physical Science, ETH Zürich, Vladimir-Prelog-Weg 2, Zürich, Switzerland. roland.riek@phys.chem.ethz.ch.ORCID 0000-0002-6333-066X
Raffaele MezzengaETH Zurich, Department of Health Sciences and Technology, Zurich, Switzerland. raffaele.mezzenga@hest.ethz.ch.ORCID 0000-0002-5739-2610

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reversible and irreversible amyloids are two diverging cases of protein (mis)folding associated with the cross-β motif in the protein folding and aggregation energy landscape. Yet, the molecular origins responsible for the formation of reversible vs irreversible amyloids have remained unknown. Here we provide evidence at the atomic level of distinct folding motifs for irreversible and reversible amyloids derived from a single protein sequence: human lysozyme. We compare the 2.8 Å structure of irreversible amyloid fibrils determined by cryo-electron microscopy helical reconstructions with molecular insights gained by solid-state NMR spectroscopy on reversible amyloids. We observe a canonical cross-β-sheet structure in irreversible amyloids, whereas in reversible amyloids, there is a less-ordered coexistence of β-sheet and helical secondary structures that originate from a partially unfolded lysozyme, thus carrying a "memory" of the original folded protein precursor. We also report the structure of hen egg-white lysozyme irreversible amyloids at 3.2 Å resolution, revealing another canonical amyloid fold, and reaffirming that irreversible amyloids undergo a complete conversion of the native protein into the cross-β structure. By combining atomic force microscopy, cryo-electron microscopy and solid-state NMR, we show that a full unfolding of the native protein precursor is a requirement for establishing irreversible amyloid fibrils.

Indexed as

AmyloidCryoelectron MicroscopyMuramidaseProtein FoldingAnimalsChickensHumansMagnetic Resonance SpectroscopyModels, MolecularProtein Structure, SecondaryAmyloidhen egg lysozymeMuramidase

Identifiers

PMID39349464
PMCPMC11442456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.